{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T21:04:48Z","timestamp":1761253488277,"version":"3.40.5"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1111\/dth.14254","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T10:16:11Z","timestamp":1598696171000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice"],"prefix":"10.1155","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4035-7955","authenticated-orcid":false,"given":"Trinidad","family":"Montero\u2010Vilchez","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Salvador\u2010Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Sanchez\u2010Diaz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-4931","authenticated-orcid":false,"given":"Carlos","family":"Cuenca\u2010Barrales","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-7317","authenticated-orcid":false,"given":"Antonio","family":"Martinez\u2010Lopez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Arias\u2010Santiago","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"},{"name":"Department of Medicine, Granada School of Medicine, Granada University  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina\u2010Leyva","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hidradenitis Suppurativa Clinic Hospital Universitario Virgen de las Nieves  Granada Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria Granada  Granada Spain"},{"name":"European Hidradenitis Suppurativa Foundation  Dessau\u2010Ro\u00dflau Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1014163"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.911"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.020"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15940"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90321-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.07.027"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15233"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"e_1_2_9_11_1","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen ARJV","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_9_12_1","unstructured":"ClinicalTrials.gov. Identifier NCT03512275 A study of bermekimab in patients with hidradenitis suppurativa; Bethesda (MD): National Library of Medicine (US). 29 Febraury 2000. April 30 2018.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03512275"},{"key":"e_1_2_9_13_1","unstructured":"ClinicalTrials.gov. Identifier NCT04242498 A study to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD II); Bethesda (MD): National Library of Medicine (US). Febraury 29 2000.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04242498"},{"key":"e_1_2_9_14_1","unstructured":"ClinicalTrials.gov. Identifier NCT04249713 An alternative dose interval study in participants with hidradenitis suppurativa receiving brodalumab; Bethesda (MD): National Library of Medicine (US). Febraury 29 2000. January 31 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04249713"},{"key":"e_1_2_9_15_1","unstructured":"ClinicalTrials.gov. Identifier NCT03628924 A Study to Evaluate the Efficacy Safety and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA); Bethesda (MD): National Library of Medicine (US). Febraury 29 2000. August 14 2018.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03628924"},{"key":"e_1_2_9_16_1","unstructured":"ClinicalTrials.gov. Identifier NCT03926169 A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa; Bethesda (MD): National Library of Medicine (US). Febraury 29 2000. April 24 2019.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03926169"},{"key":"e_1_2_9_17_1","unstructured":"ClinicalTrials.gov. Identifier NCT03713632 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE); Bethesda (MD): National Library of Medicine (US). Febraury 29 2000. October 22 2018.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03713632"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14475"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0090"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16328"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001916"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15572"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15878"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"issue":"5","key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew JW","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.19165","article-title":"First real\u2010world data provide evidence for a 'window of opportunity' in treatment of hidradenitis suppurativa\/acne inversa","author":"Zouboulis CC","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_31_1","unstructured":"US Food and Drug Administration.HUMIRA (adalimumab) injection for subcutaneous use. 2008.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s0110lbl.pdf"},{"key":"e_1_2_9_32_1","unstructured":"European Medicines Agency.Humira: EPAR\u2010Product Information2020.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/humira\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"issue":"20","key":"e_1_2_9_34_1","first-page":"30834","article-title":"The effect of subcutaneous brodalumab upon clinical disease activity in hidradenitis suppurativa: an open label cohort study","volume":"0190","author":"Frew JW","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15710"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12737"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13245"},{"issue":"4","key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/ced.14127","article-title":"Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab","volume":"45","author":"Caposiena Caro RD","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_9_39_1","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \"window of opportunity\" in hidradenitis suppurativa treated with adalimumab: a retrospective, real\u2010life multicenter cohort study","author":"Marzano AV","year":"2020","journal-title":"Br J Dermatol"},{"key":"e_1_2_9_40_1","unstructured":"ClinicalTrials.gov. Identifier NCT02808975 Safety and efficacy of humira (Adalimumab) for hidradenitis suppurativa (HS) peri\u2010surgically (SHARPS Study) (SHARPS); Bethesda (MD): National Library of Medicine (US). Febraury 29 2000. June 22 2016.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02808975."},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000000584"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15706"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.14254","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dth.14254","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dth.14254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:59:17Z","timestamp":1671818357000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.14254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/dth.14254"],"URL":"https:\/\/doi.org\/10.1111\/dth.14254","archive":["Portico"],"relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"type":"print","value":"1396-0296"},{"type":"electronic","value":"1529-8019"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"2020-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}